Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 9/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548176 | 0.90 | ESR2 (0.69) | ESR2HDAC1NR1H2NAMPTDDB1 | |
| SCHEMBL2416879 | 0.90 | NR1H2 (0.67) | ESR2HDAC1NR1H2NAMPTDDB1 | |
| SCHEMBL451998 | 0.90 | ESR2 (0.69) | ESR2HDAC1NR1H2NAMPTDDB1 | |
| SCHEMBL29586616 | 0.90 | NR1H2 (0.67) | ESR2HDAC1NR1H2NAMPTDDB1 | |
| SCHEMBL24265587 | 0.87 | NR1H2 (0.58) | ESR2HDAC1NR1H2NAMPTDDB1 | |
| SCHEMBL2995065 | 0.87 | ESR2 (0.59) | ESR2HDAC1NR1H2NAMPTDDB1 | |
| SCHEMBL30548188 | 0.87 | NR1H2 (0.58) | ESR2HDAC1NR1H2NAMPTDDB1 | |
| SCHEMBL24215797 | 0.86 | ESR2 (0.53) | ESR2HDAC1NR1H2NAMPTDDB1 | |
| SCHEMBL2123156 | 0.84 | ESR2 (0.57) | ESR2NR1H2GPR119DRD2 | |
| SCHEMBL7675148 | 0.82 | NR1H2 (0.50) | ESR2HDAC1NR1H2NAMPTDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678644-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Yidi Biotechnology Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025021182-A1 | CYP11A1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-01-30 | — | — | WO | disclosed |
| WO-2023116835-A1 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | 苏州开拓药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
| EP-4149924-A1 | CYP11A1 INHIBITORS | Orion Corporation (FI) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551831-A | CYP11A1 inhibitor | 奥赖恩公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021229152-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021218755-A1 | SHP2 INHIBITOR, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | disclosed |
| WO-2007122156-A1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| EP-1554243-B1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| EP-1119562-B1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| US-20030158222-A1 | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | SMITHKLINE BEECHAM P.L.C. | 2003-08-21 | — | — | US | disclosed |
| US-6521638-B1 | Such as 2-(2-(1-(4-(3-(3-methanesulfonyl)phenylpropenoyl)-amino)cyclohexyl)ethyl) -2,3-dihydro-1H-isoindole; amidation of amine and carbonyl halide | SMITHKLINE BEECHAM P.L.C. (DE) | 2003-02-18 | — | — | US | disclosed |
| EP-1119562-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021950-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | HRH3, HRH4, HRH1 | ESR2 1745/4885HDAC1 79/4885NR1H2 992/4885 |
| US-20230192677-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP11B2, CYP17A1 | ESR2 118/4885HDAC1 802/4885NR1H2 75/4885 |
| US-20030158222-A1 | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | OPRD1, DRD3, OPRM1 | ESR2 585/4885HDAC1 1709/4885NR1H2 74/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | ESR2 3116/4885HDAC1 43/4885NR1H2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.